Appia Bio launches to develop stem cell-based cell therapies
Appia Bio has launched from stealth as an early-stage biotechnology company focused on the development of engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients. The company will be initially backed by $52 million in financing. Read More
Gennao Bio nabs $40M for its gene monoclonal antibody platform
Gennao Bio has closed $40 million in financing to support the advancement of its proprietary gene monoclonal antibody platform and the development of targeted nucleic acid therapeutic product candidates for the treatment of cancer and rare monogenic skeletal muscle diseases. Read More
Flagship Pioneering unveils eRNA platform from Laronde
Flagship Pioneering unveiled its Laronde platform for the development of endless RNA (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. The company has initially committed $50 million to support the development of the platform and initial pipeline medicines. Read More
CRISPR Therapeutics, Nkarta partner on gene edited cancer therapies
CRISPR Therapeutics has established a strategic partnership with Nkarta to research, develop, and commercialize CRISPR/Cas9 gene edited cell therapies for cancer. Read More
Bio-Techne posts revenue gains in Q3
Bio-Techne reported strong growth in revenues for its third quarter, thanks largely to sales in its protein analysis business. Read More
Dyno Therapeutics nabs $100M for AI gene therapy platform
Dyno Therapeutics has closed $100 million in financing to expand its CapsidMap platform, which uses artificial intelligence (AI) technology to design novel adeno-associated virus gene therapy vectors, thereby enhancing the therapeutic effect of gene therapies. Read More
Errant Gene Therapeutics changes name to San Rocco Therapeutics
Errant Gene Therapeutics, founded in 1993 after founder Pat Girondi's son was diagnosed with thalassemia, will become San Rocco Therapeutics, after San Rocco, the patron saint of hopeless disease. Read More
Cellares raises $82M to make scalable 'factory-in-a-box'
Life sciences technology company Cellares has raised $82 million in financing to accelerate the development of the scalable factory-in-a-box Cell Shuttle. Read More
Athenex to acquire Kuur to develop cell therapies
Athenex plans to acquire Kurr Therapeutics to expand its cell therapy development. Read More
Affinia secures $110M to move gene therapies to clinic
Affinia Therapeutics has closed $110 million in financing to further develop its proprietary gene therapy platform, to advance its programs to the clinic, and for general corporate purposes. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter